Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 24;8(4):558.
doi: 10.3390/jcm8040558.

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer

Affiliations

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer

Jennifer Eriksson et al. J Clin Med. .

Abstract

The study objective was to assess US physicians' Mismatch Repair/Microsatellite Instability (MMR/MSI) testing practices for metastatic colorectal cancer (mCRC) patients. A non-interventional, cross-sectional online survey was conducted among 151 physicians (91 oncologists, 15 surgeons and 45 pathologists) treating mCRC patients in the US. Eligible physicians were US-based with at least 5 years of experience treating CRC patients, had at least one mCRC patient in their routine care in the past 6 months, and had ordered at least one MMR/MSI test for CRC in the past 6 months. Descriptive and logistic regression analyses were performed. Awareness of specific MMR/MSI testing guidelines was high (n = 127, 84.1%). Of those, 93.7% (119/127) physicians had awareness of specific published guidelines with majority 67.2% (80/119) being aware of National Comprehensive Cancer Network (NCCN) guidelines. Universal testing for all CRC patients was performed by 68.9% (104/151) physicians, while 29.8% (45/151) selectively order the test for some CRC patients. Key barriers for testing included insufficient tissue sample (48.3%, 73/151), patient declined to have the test done (35.8%, 54/151) and insurance cost concerns for patients (31.1%, 47/151), while 27.2% (41/151) reported no barriers. The survey demonstrated high awareness and compliance with MMR/MSI testing guidelines although universal testing rates seem to be suboptimal.

Keywords: colorectal cancer; mismatch repair/microsatellite instability testing; survey.

PubMed Disclaimer

Conflict of interest statement

J.E., J.L., G.A.-J., M.M. are employed by ICON plc, a contract research organization conducting research on behalf of pharmaceutical companies. M.A., M.C., M.V., and L.K. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Figures

Figure 1
Figure 1
Reasons and barriers for ordering MMR/MSI testing—% of physicians agreeing with each statement. * Multiple selections were allowed. Thus, total percentage will not add up to 100%. ** Answer included: eligibility for certain therapies, and compliance with guidelines. *** Answer included: Patients do not go to third line.
Figure 2
Figure 2
Physician discussion with patients—% of physicians agreeing with each statement. * Multiple selections were allowed. Thus, total percentage will not add up to 100%. ** Referral to genetic counselling.

References

    1. Siegel R.L., Miller K., Jemal A. Cancer Statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Crooke H., Kobayashi M., Mitchell B., Nwokeji E., Laurie M., Kamble S., McKenna M., Masood A., Korytowsky B. Estimating 1- and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014. J. Clin. Oncol. 2018;36:587. doi: 10.1200/JCO.2018.36.4_suppl.587. - DOI
    1. Yabroff K.R., Lund J., Kepka D., Mariotto A. Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol. Biomark. Prev. 2011;20:2006–2014. doi: 10.1158/1055-9965.EPI-11-0650. - DOI - PMC - PubMed
    1. Ansa B.E., Coughlin S.S., Alema-Mensah E., Smith S.A. Evaluation of colorectal cancer incidence trends in the United States (2000–2014) J. Clin. Med. 2018;7:22. doi: 10.3390/jcm7020022. - DOI - PMC - PubMed
    1. Kindler H.L., Shulman K.L. Metastatic colorectal cancer. Curr. Treat. Options Oncol. 2001;2:459–471. doi: 10.1007/s11864-001-0068-7. - DOI - PubMed

LinkOut - more resources